Single‐ and Double‐Chain Recombinant Tissue Plasminogen Activator: A Review of Efficacy and Safety

R.G. Wilcox, C.G. Olsson, A.M. Skene, G. Von Der Lippe, G. Jensen, J.R. Hampton, For The Asset Study Group, TRIAL OF TISSUE PLASMINOGEN ACTIVATOR FOR MORTALITY REDUCTION IN ACUTE MYOCARDIAL INFARCTION: Anglo-Scandinavian Study of Early Thrombolysis (ASSET) The Lancet. ,vol. 332, pp. 525- 530 ,(1988) , 10.1016/S0140-6736(88)92656-6

Marc Verstraete, Alfred E.R. Arnold, Ronald W. Brower, Désiré Collen, David P. de Bono, Chris De Zwaan, Rainer Erbel, W.Stuart Hillis, R.John Lennane, Jacobus Lubsen, Detlef Mathey, Douglas S. Reid, Wolfgang Rutsch, Michael Schartl, Joachim Schofer, Patrick W. Serruys, Maarten L. Simoons, Rainer Uebis, Alec Vahanian, Freek W.A. Verheugt, Rainer von Essen, Acute coronary thrombolysis with recombinant human tissue-type plasminogen activator: initial patency and influence of maintained infusion on reocclusion rate. American Journal of Cardiology. ,vol. 60, pp. 231- 237 ,(1987) , 10.1016/0002-9149(87)90219-0

Alan J. Tiefenbrunn, Coronary Thrombolysis— It's Worth the Risk JAMA: The Journal of the American Medical Association. ,vol. 261, pp. 2107- 2108 ,(1989) , 10.1001/JAMA.1989.03420140109036

Burton E. Sobel, Safety and efficacy of tissue-type plasminogen activator produced by recombinant DNA technology. Journal of the American College of Cardiology. ,vol. 10, pp. 40- ,(1987) , 10.1016/S0735-1097(87)80427-8

F. Van de Werf, A. E. Arnold, Intravenous tissue plasminogen activator and size of infarct, left ventricular function, and survival in acute myocardial infarction. BMJ. ,vol. 297, pp. 1374- 1379 ,(1988) , 10.1136/BMJ.297.6660.1374

BS George, DJ Kereiakes, DC Stump, RJ Candela, CW Abbottsmith, L Aronson, A Pickel, JM Boswick, KL Lee, SG Ellis, RM Calii, TAMI Study Group, A randomized controlled trial of intravenous tissue plasminogen activator and early intravenous heparin in acute myocardial infarction. Circulation. ,vol. 79, pp. 281- 286 ,(1989) , 10.1161/01.CIR.79.2.281

J H Chesebro, G Knatterud, R Roberts, J Borer, L S Cohen, J Dalen, H T Dodge, C K Francis, D Hillis, P Ludbrook, Thrombolysis in Myocardial Infarction (TIMI) Trial, Phase I: A comparison between intravenous tissue plasminogen activator and intravenous streptokinase. Clinical findings through hospital discharge. Circulation. ,vol. 76, pp. 142- 154 ,(1987) , 10.1161/01.CIR.76.1.142

C L Lucore, E T Fry, D A Nachowiak, B E Sobel, Biochemical determinants of clearance of tissue-type plasminogen activator from the circulation. Circulation. ,vol. 77, pp. 906- 914 ,(1988) , 10.1161/01.CIR.77.4.906

Eric J. Topol, Douglas C. Morris, Richard W. Smalling, Richard R. Schumacher, Charles R. Taylor, Akira Nishikawa, Henry A. Liberman, Désiré Collen, Margaret E. Tufte, Elliott B. Grossbard, William W. O’Neill, A multicenter, randomized, placebo-controlled trial of a new form of intravenous recombinant tissue-type plasminogen activator (activase) in acute myocardial infarction. Journal of the American College of Cardiology. ,vol. 9, pp. 1205- 1213 ,(1987) , 10.1016/S0735-1097(87)80457-6

Eugene Braunwald, Thrombolytic reperfusion of acute myocardial infarction: resolved and unresolved issues. Journal of the American College of Cardiology. ,vol. 12, ,(1988) , 10.1016/0735-1097(88)92645-9